Therefore, this prospective study addresses the efficacy of cetuximab monotherapy compared to combination with irinotecan in two molecularly defined subpopulations of patients with refractory metastatic colorectal cancer, either “quadruple wild type” tumours or KRAS G13D mutated tumours. Here, KRAS is linked to metastatic colorectal cancer.